| 000 | 01083 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250513210101.0 | ||
| 264 | 0 | _c20000608 | |
| 008 | 200006s 0 0 eng d | ||
| 022 | _a0163-4356 | ||
| 024 | 7 |
_a10.1097/00007691-200004000-00001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRasmussen, B B | |
| 245 | 0 | 0 |
_aIs therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? _h[electronic resource] |
| 260 |
_bTherapeutic drug monitoring _cApr 2000 |
||
| 300 |
_a143-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xphysiology |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aSelective Serotonin Reuptake Inhibitors _xblood |
| 700 | 1 | _aBrøsen, K | |
| 773 | 0 |
_tTherapeutic drug monitoring _gvol. 22 _gno. 2 _gp. 143-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00007691-200004000-00001 _zAvailable from publisher's website |
| 999 |
_c10727611 _d10727611 |
||